JP2012519728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519728A5 JP2012519728A5 JP2011553553A JP2011553553A JP2012519728A5 JP 2012519728 A5 JP2012519728 A5 JP 2012519728A5 JP 2011553553 A JP2011553553 A JP 2011553553A JP 2011553553 A JP2011553553 A JP 2011553553A JP 2012519728 A5 JP2012519728 A5 JP 2012519728A5
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- preconcentrate
- mixtures
- acid
- dha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 120
- 239000003921 oil Substances 0.000 claims 86
- 235000019198 oils Nutrition 0.000 claims 86
- 235000014113 dietary fatty acids Nutrition 0.000 claims 75
- 239000000194 fatty acid Substances 0.000 claims 75
- 229930195729 fatty acid Natural products 0.000 claims 75
- 150000004665 fatty acids Chemical class 0.000 claims 70
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 68
- -1 sulfate ethers Chemical class 0.000 claims 63
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 56
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 56
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 56
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 56
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 48
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 46
- 239000004094 surface-active agent Substances 0.000 claims 36
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 34
- 229960003511 macrogol Drugs 0.000 claims 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 15
- 239000004359 castor oil Substances 0.000 claims 15
- 235000019438 castor oil Nutrition 0.000 claims 15
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 15
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 12
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 12
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 12
- 239000012141 concentrate Substances 0.000 claims 12
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 12
- 238000012377 drug delivery Methods 0.000 claims 12
- 125000004494 ethyl ester group Chemical group 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 10
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 claims 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 10
- 239000004698 Polyethylene Substances 0.000 claims 10
- 229920002675 Polyoxyl Polymers 0.000 claims 10
- 229920001213 Polysorbate 20 Polymers 0.000 claims 10
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 10
- 239000002736 nonionic surfactant Substances 0.000 claims 10
- 150000003904 phospholipids Chemical group 0.000 claims 10
- 229920000573 polyethylene Polymers 0.000 claims 10
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 10
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 10
- 229920001451 polypropylene glycol Polymers 0.000 claims 10
- 229940068977 polysorbate 20 Drugs 0.000 claims 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 9
- 229920000053 polysorbate 80 Polymers 0.000 claims 9
- 229940068968 polysorbate 80 Drugs 0.000 claims 9
- 239000003963 antioxidant agent Substances 0.000 claims 8
- 230000003078 antioxidant effect Effects 0.000 claims 8
- 235000006708 antioxidants Nutrition 0.000 claims 8
- 150000001298 alcohols Chemical class 0.000 claims 7
- 150000003626 triacylglycerols Chemical class 0.000 claims 7
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 6
- OQOCQFSPEWCSDO-JLNKQSITSA-N 6Z,9Z,12Z,15Z,18Z-Heneicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O OQOCQFSPEWCSDO-JLNKQSITSA-N 0.000 claims 6
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims 6
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims 6
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 claims 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 6
- 235000021342 arachidonic acid Nutrition 0.000 claims 6
- 229940114079 arachidonic acid Drugs 0.000 claims 6
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical group COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 6
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims 6
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 claims 6
- OQOCQFSPEWCSDO-UHFFFAOYSA-N heneicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCC(O)=O OQOCQFSPEWCSDO-UHFFFAOYSA-N 0.000 claims 6
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 6
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 6
- 239000006014 omega-3 oil Substances 0.000 claims 6
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims 6
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 claims 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 5
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 5
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims 5
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims 5
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims 5
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims 5
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 5
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 5
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims 5
- 229920001219 Polysorbate 40 Polymers 0.000 claims 5
- 229930006000 Sucrose Natural products 0.000 claims 5
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 5
- 150000008051 alkyl sulfates Chemical class 0.000 claims 5
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 5
- 239000003945 anionic surfactant Substances 0.000 claims 5
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 claims 5
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 5
- 229960001950 benzethonium chloride Drugs 0.000 claims 5
- 239000003833 bile salt Substances 0.000 claims 5
- 229940093761 bile salts Drugs 0.000 claims 5
- ABDBNWQRPYOPDF-UHFFFAOYSA-N carbonofluoridic acid Chemical compound OC(F)=O ABDBNWQRPYOPDF-UHFFFAOYSA-N 0.000 claims 5
- 239000003093 cationic surfactant Substances 0.000 claims 5
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims 5
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 5
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims 5
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims 5
- 229920001577 copolymer Polymers 0.000 claims 5
- UYAAVKFHBMJOJZ-UHFFFAOYSA-N diimidazo[1,3-b:1',3'-e]pyrazine-5,10-dione Chemical compound O=C1C2=CN=CN2C(=O)C2=CN=CN12 UYAAVKFHBMJOJZ-UHFFFAOYSA-N 0.000 claims 5
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 claims 5
- UQSQSQZYBQSBJZ-UHFFFAOYSA-N fluorosulfonic acid Chemical class OS(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-N 0.000 claims 5
- 229940049654 glyceryl behenate Drugs 0.000 claims 5
- 229940074045 glyceryl distearate Drugs 0.000 claims 5
- 229940075507 glyceryl monostearate Drugs 0.000 claims 5
- 229920001477 hydrophilic polymer Polymers 0.000 claims 5
- 229920001600 hydrophobic polymer Polymers 0.000 claims 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 5
- 229940072106 hydroxystearate Drugs 0.000 claims 5
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims 5
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 claims 5
- 229940066429 octoxynol Drugs 0.000 claims 5
- 229920002113 octoxynol Polymers 0.000 claims 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 5
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 5
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims 5
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims 5
- 229940101027 polysorbate 40 Drugs 0.000 claims 5
- 229940116423 propylene glycol diacetate Drugs 0.000 claims 5
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 5
- 150000003235 pyrrolidines Chemical class 0.000 claims 5
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims 5
- 239000005720 sucrose Substances 0.000 claims 5
- 239000002888 zwitterionic surfactant Substances 0.000 claims 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 4
- 241000195493 Cryptophyta Species 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 239000005642 Oleic acid Substances 0.000 claims 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 235000021323 fish oil Nutrition 0.000 claims 4
- 239000007903 gelatin capsule Substances 0.000 claims 4
- 230000005802 health problem Effects 0.000 claims 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 4
- 230000000813 microbial effect Effects 0.000 claims 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 4
- PWVUXRBUUYZMKM-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCO PWVUXRBUUYZMKM-UHFFFAOYSA-N 0.000 claims 3
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims 3
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 239000000839 emulsion Substances 0.000 claims 3
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims 3
- 229960004488 linolenic acid Drugs 0.000 claims 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 3
- 229920000847 nonoxynol Polymers 0.000 claims 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 3
- 229940113124 polysorbate 60 Drugs 0.000 claims 3
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 claims 3
- 229960003656 ricinoleic acid Drugs 0.000 claims 3
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 claims 3
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 150000004996 alkyl benzenes Chemical class 0.000 claims 2
- 229940087168 alpha tocopherol Drugs 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 238000004094 preconcentration Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 229940075554 sorbate Drugs 0.000 claims 2
- 229940114926 stearate Drugs 0.000 claims 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 claims 2
- 229960000984 tocofersolan Drugs 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 239000002076 α-tocopherol Substances 0.000 claims 2
- 235000004835 α-tocopherol Nutrition 0.000 claims 2
- 206010014486 Elevated triglycerides Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 108010069201 VLDL Cholesterol Proteins 0.000 claims 1
- 230000009084 cardiovascular function Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000004064 cosurfactant Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000030363 nerve development Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 230000004382 visual function Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15861309P | 2009-03-09 | 2009-03-09 | |
| US61/158,613 | 2009-03-09 | ||
| US24263009P | 2009-09-15 | 2009-09-15 | |
| US61/242,630 | 2009-09-15 | ||
| US25429309P | 2009-10-23 | 2009-10-23 | |
| US25429109P | 2009-10-23 | 2009-10-23 | |
| US61/254,291 | 2009-10-23 | ||
| US61/254,293 | 2009-10-23 | ||
| PCT/IB2010/000824 WO2010103404A1 (en) | 2009-03-09 | 2010-03-09 | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015253166A Division JP6723009B2 (ja) | 2009-03-09 | 2015-12-25 | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012519728A JP2012519728A (ja) | 2012-08-30 |
| JP2012519728A5 true JP2012519728A5 (cg-RX-API-DMAC10.html) | 2013-07-25 |
| JP6176894B2 JP6176894B2 (ja) | 2017-08-09 |
Family
ID=42727856
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553553A Active JP6176894B2 (ja) | 2009-03-09 | 2010-03-09 | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 |
| JP2015253166A Active JP6723009B2 (ja) | 2009-03-09 | 2015-12-25 | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 |
| JP2018018093A Pending JP2018090600A (ja) | 2009-03-09 | 2018-02-05 | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 |
| JP2020018504A Active JP7199389B2 (ja) | 2009-03-09 | 2020-02-06 | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015253166A Active JP6723009B2 (ja) | 2009-03-09 | 2015-12-25 | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 |
| JP2018018093A Pending JP2018090600A (ja) | 2009-03-09 | 2018-02-05 | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 |
| JP2020018504A Active JP7199389B2 (ja) | 2009-03-09 | 2020-02-06 | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 |
Country Status (17)
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102421422A (zh) * | 2009-03-09 | 2012-04-18 | 普罗诺瓦生物医药挪威公司 | 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途 |
| US8207363B2 (en) | 2009-03-19 | 2012-06-26 | Martek Biosciences Corporation | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof |
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| MX377553B (es) | 2009-04-29 | 2025-03-10 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| BRPI1011883A2 (pt) | 2009-06-15 | 2016-09-13 | Amarin Pharma Inc | uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina |
| NZ599061A (en) | 2009-09-23 | 2014-05-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| ES2661812T3 (es) * | 2009-10-16 | 2018-04-04 | Mochida Pharmaceutical Co., Ltd. | Composiciones |
| ES2895477T3 (es) * | 2009-10-23 | 2022-02-21 | Basf As | Cápsulas y comprimidos revestidos de una mezcla de aceites de ácidos grasos |
| EP3335713B1 (en) | 2009-10-29 | 2022-08-31 | Acasti Pharma, Inc. | Concentrated therapeutic phospholipid compositions |
| US9321715B2 (en) | 2009-12-30 | 2016-04-26 | Basf Pharma (Callanish) Limited | Simulated moving bed chromatographic separation process |
| CA2993690C (en) | 2010-01-19 | 2022-03-22 | Dsm Ip Assets B.V. | Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof |
| US11236351B2 (en) | 2010-05-17 | 2022-02-01 | Dow Agrosciences Llc | Production of DHA and other LC PUFAs in plants |
| JP2013537186A (ja) * | 2010-09-08 | 2013-09-30 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂肪酸油混合物と遊離脂肪酸とスタチンとを含む組成物 |
| KR20130139896A (ko) * | 2010-09-08 | 2013-12-23 | 프로노바 바이오파마 너지 에이에스 | 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물 |
| WO2012032414A2 (en) * | 2010-09-08 | 2012-03-15 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture, a surfactant, and a statin |
| SG10201509127YA (en) * | 2010-11-05 | 2015-12-30 | Pronova Biopharma Norge As | Methods of treatment using lipid compounds |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US8951514B2 (en) * | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| US20120302639A1 (en) * | 2011-02-16 | 2012-11-29 | Pivotal Therapeutics Inc. | Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death |
| US9119826B2 (en) * | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| JP2014506891A (ja) * | 2011-02-16 | 2014-03-20 | ピヴォタル セラピューティクス インコーポレイテッド | 心血管疾患（ＣＶＤ）患者の食事管理のためのω３脂肪酸診断アッセイ |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| EP2675446A1 (en) * | 2011-02-16 | 2013-12-25 | Pivotal Therapeutics, Inc. | Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease |
| JP2014505732A (ja) * | 2011-02-16 | 2014-03-06 | ピヴォタル セラピューティクス インコーポレイテッド | 心血管疾患において用いるための、スタチンおよびω３脂肪酸（ＥＰＡ、ＤＨＡおよびＤＰＡ） |
| JP2014505729A (ja) * | 2011-02-16 | 2014-03-06 | ピヴォタル セラピューティクス インコーポレイテッド | コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤（アゼチジノン）およびω３脂肪酸（ＥＰＡ、ＤＨＡ、ＤＰＡ） |
| US8952000B2 (en) * | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| US8697676B2 (en) * | 2011-06-15 | 2014-04-15 | Ronald E Rosedale | Omega-3 fatty acid nutriceutical composition and optimization method |
| US8865685B2 (en) | 2011-06-30 | 2014-10-21 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
| GB201111591D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | Further new process |
| GB201111601D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New process |
| GB201111594D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New improved process |
| GB201111595D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | Improved process |
| GB201111589D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New modified process |
| MX342216B (es) | 2011-07-21 | 2016-09-20 | Dsm Ip Assets Bv | Composiciones de acidos grasos. |
| EP2734626B1 (en) * | 2011-07-21 | 2020-12-16 | DSM IP Assets B.V. | Microbial oils enriched in polyunsaturated fatty acids |
| TW201307553A (zh) | 2011-07-26 | 2013-02-16 | 陶氏農業科學公司 | 在植物中生產二十二碳六烯酸（ｄｈａ）及其他長鏈多元不飽和脂肪酸（ｌｃ－ｐｕｆａ）之技術 |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| WO2013072767A1 (en) * | 2011-11-18 | 2013-05-23 | Pronova Biopharma Norge As | Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture |
| CN107050457A (zh) | 2012-01-06 | 2017-08-18 | 翁特拉制药公司 | 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物 |
| US9452135B2 (en) | 2012-03-20 | 2016-09-27 | Particle Dynamics International, Llc | Gelling agent-based dosage form |
| US20160228397A1 (en) * | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
| IN2014DN08449A (cg-RX-API-DMAC10.html) * | 2012-03-30 | 2015-05-08 | Sancilio & Company Inc | |
| US10898458B2 (en) * | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
| US20150132389A1 (en) * | 2012-03-30 | 2015-05-14 | Sancilio & Company, Inc. | Omega-3 Fatty Acid Ester Compositions |
| US20150125529A1 (en) * | 2012-03-30 | 2015-05-07 | Sancilio & Company, Inc. | Omega-3 Fatty Acid Ester Compositions |
| US9480651B2 (en) * | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
| KR20150028233A (ko) | 2012-05-07 | 2015-03-13 | 옴테라 파마슈티칼스, 인크. | 스타틴 및 오메가-３ 지방산의 조성물 |
| US9540306B2 (en) | 2012-05-14 | 2017-01-10 | Nippon Suisan Kaisha, Ltd. | Highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester with reduced environmental pollutants, and method for producing same |
| US20140194512A1 (en) * | 2012-06-17 | 2014-07-10 | Matinas Biopharma, Inc. | Compositions comprising docosapentaenoic acid and methods of use |
| WO2013192109A1 (en) * | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| CN103015230B (zh) * | 2012-11-27 | 2015-04-01 | 广州嘉德乐生化科技有限公司 | 一种单硬脂酸甘油酯和聚氧乙烯醚脂肪酸皂的组合物 |
| KR20150103009A (ko) * | 2012-12-06 | 2015-09-09 | 마티나스 바이오파마, 인코포레이티드 | 도코사펜타에노산을 포함하는 조성물의 투여 |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| GB201300354D0 (en) | 2013-01-09 | 2013-02-20 | Basf Pharma Callanish Ltd | Multi-step separation process |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US11351139B2 (en) | 2013-02-28 | 2022-06-07 | Basf As | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
| EP2968246A4 (en) * | 2013-03-13 | 2016-08-03 | Matinas Biopharma Inc | OMEGA-3-PENTAIC ACID COMPOSITIONS AND METHODS OF USE |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US20140322314A1 (en) * | 2013-04-29 | 2014-10-30 | Matinas Biopharma, Inc. | Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment |
| US8802880B1 (en) | 2013-05-07 | 2014-08-12 | Group Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
| US9428711B2 (en) | 2013-05-07 | 2016-08-30 | Groupe Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
| CA2918330C (en) | 2013-07-18 | 2022-08-30 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of .omega.3 fatty acid |
| EP3023098B1 (en) | 2013-07-18 | 2020-06-24 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of omega-3 fatty acid |
| WO2015011724A2 (en) * | 2013-07-22 | 2015-01-29 | Kms Health Center Pvt Ltd | A novel omega -3 fatty acid composition with a plant extract |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| EP2883860B1 (fr) | 2013-12-11 | 2016-08-24 | Novasep Process | Procédé chromatographique de production d'acides gras polyinsaturés |
| BR112016014262B1 (pt) | 2013-12-20 | 2022-04-05 | MARA Renewables Corporation | Método para recuperar lipídeos de uma população de micro-organismos |
| JP6303017B2 (ja) | 2014-01-07 | 2018-03-28 | ノヴァセプ プロセスＮｏｖａｓｅｐ Ｐｒｏｃｅｓｓ | 芳香族アミノ酸を精製する方法 |
| WO2015113987A1 (en) * | 2014-01-28 | 2015-08-06 | Fresenius Kabi Deutschland Gmbh | Composition comprising epa and dha triglycerides for parenteral administration |
| EA038458B1 (ru) | 2014-04-09 | 2021-08-31 | Палс Фармасьютикалс Пвт. Лтд. | Стабильная водная нанодисперсия водонерастворимых биоактивных соединений и способ ее получения |
| TWI725937B (zh) * | 2014-06-06 | 2021-05-01 | 美商海洋原料公司 | ω-３組成物、劑型及使用方法 |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| CN114917328B (zh) * | 2014-11-05 | 2025-06-20 | 雅培制药股份有限公司 | 用于生产具有改善的安全特性的具有脂肪酶活性的组合物和适用于药物用途的组合物的方法 |
| CN105614638A (zh) * | 2014-11-28 | 2016-06-01 | 深圳市前海安测信息技术有限公司 | Dha纳米乳及其制备方法和其在健康保健饮品中的应用 |
| US10561627B2 (en) * | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
| US11007161B1 (en) * | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
| KR102488648B1 (ko) | 2015-01-21 | 2023-01-12 | 모치다 세이야쿠 가부시키가이샤 | ω3 지방산의 자기 유화 조성물 |
| EP3305756B1 (en) * | 2015-06-02 | 2022-01-05 | Noster Inc. | Novel triglyceride and use thereof |
| RU2655803C2 (ru) * | 2016-03-10 | 2018-05-29 | АД Смарт, СИА | Фармацевтическая композиция для профилактики и лечения атеросклероза |
| WO2017158439A1 (en) * | 2016-03-16 | 2017-09-21 | Omegatri As | Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production |
| US10851395B2 (en) | 2016-06-10 | 2020-12-01 | MARA Renewables Corporation | Method of making lipids with improved cold flow properties |
| CN106072611A (zh) * | 2016-06-20 | 2016-11-09 | 威海百合生物技术股份有限公司 | 一种含不饱和脂肪酸的多相稀释组合物 |
| GB201611920D0 (en) * | 2016-07-08 | 2016-08-24 | Astrazeneca Ab | Pharmaceutical compositions |
| AU2017301077B2 (en) * | 2016-08-12 | 2022-07-07 | Pharmako Biotechnologies Pty Limited | Omega-3 compositions and methods relating thereto |
| WO2018054265A1 (zh) * | 2016-09-20 | 2018-03-29 | 张碧婷 | 亲水性脂类组合物的包装组合物，其制备及调配方法和应用 |
| EP3559206B1 (en) | 2016-12-22 | 2025-12-03 | Mara Renewables Corporation | Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism |
| CN107048405A (zh) * | 2017-03-03 | 2017-08-18 | 武汉锶博睿医药技术有限公司 | 脂肪酸组件微胶囊及其制备方法 |
| GR1009542B (el) | 2018-04-25 | 2019-06-07 | Φαρματεν Α.Β.Ε.Ε. | Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων |
| EP3586641A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| EP3586642A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Ala enriched polyunsaturated fatty acid compositions |
| EP3586643A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| MA50490A (fr) | 2018-09-24 | 2020-09-02 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| BR112021010240A2 (pt) | 2018-11-30 | 2021-08-17 | Evonik Operations Gmbh | preparação que compreende uma dispersão de fosfolipídeos e sais de ácidos graxos |
| JP2022529982A (ja) | 2019-04-18 | 2022-06-27 | アーケシュフース ウニヴェルスィテーツスィーケフース ハーエフ | ＦＦＡＲ４アゴニストと、α７ ｎＡＣｈＲアゴニスト又はポジティブモジュレーターとを含む併用療法 |
| KR102096391B1 (ko) * | 2019-10-11 | 2020-04-06 | (주)아이엠디팜 | 액상결정 구조체를 형성하는 오메가-3-지방산 조성물 |
| CN110584084A (zh) * | 2019-10-17 | 2019-12-20 | 广州白云山汉方现代药业有限公司 | 一种乳化稳定剂及含该乳化稳定剂的营养乳液 |
| CA3160676A1 (en) | 2019-11-12 | 2021-05-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| IL297000A (en) | 2020-04-03 | 2022-12-01 | Mara Renewables Corp | Microbial oils with high levels of omega-3 fatty acids |
| CN113827547A (zh) * | 2020-06-23 | 2021-12-24 | 南京清普生物科技有限公司 | 一种缓释制剂组合物 |
| CN111729125B (zh) * | 2020-07-31 | 2022-10-04 | 陕西佰傲再生医学有限公司 | 骨止血材料 |
| JP2021008518A (ja) * | 2020-10-21 | 2021-01-28 | 持田製薬株式会社 | ω３脂肪酸の自己乳化組成物 |
| US20240216311A1 (en) | 2020-12-31 | 2024-07-04 | The Governing Council Of The University Of Toronto | Fully-dilutable, self-microemulsifying delivery systems (smedds) for poorly water-soluble polar solutes |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN116407543B (zh) * | 2021-12-29 | 2025-12-12 | 中国科学院上海药物研究所 | Epa-ee纳米脂质组合物、及其制剂、制备方法和应用 |
| KR20230161551A (ko) * | 2022-05-18 | 2023-11-28 | 부광약품 주식회사 | 제제학적으로 안정성이 향상된 연질 캡슐 |
| KR102895710B1 (ko) * | 2022-11-24 | 2025-12-05 | 주식회사 노바웰스 | 자가유화전달시스템을 이용한 지용성 생리활성성분의 흡수력 증대를 위한 조성물 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5312473B1 (cg-RX-API-DMAC10.html) | 1971-05-24 | 1978-05-01 | ||
| GB2033745B (en) * | 1978-05-26 | 1983-08-17 | Wellcome Found | Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions |
| PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| AU552068B2 (en) | 1981-09-21 | 1986-05-22 | Asama Chemical Co. Ltd. | Preservation of edible oils |
| ATE55056T1 (de) | 1982-12-09 | 1990-08-15 | Advanced Drug Tech | Einfach absorbierbare fettsaeureemulsionen. |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4843095A (en) * | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US5035896A (en) | 1988-06-15 | 1991-07-30 | Warner-Lambert Company | Water insoluble drugs coated by coacervated fish gelatin |
| GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| US5532002A (en) * | 1989-08-17 | 1996-07-02 | Cortecs Limited | Gelatin pharmaceutical formulations |
| CA2063791C (en) | 1989-08-17 | 2000-12-19 | Michael John Story | Hard gelatine capsule containing fat-soluble nutrients. |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5501077A (en) * | 1994-05-27 | 1996-03-26 | Springwell Dispensers, Inc. | Thermoelectric water chiller |
| JPH0889167A (ja) | 1994-09-27 | 1996-04-09 | Nippon Oil & Fats Co Ltd | 多価不飽和脂肪酸含有醗酵乳の製造方法 |
| MY118354A (en) | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
| GB9509764D0 (en) | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
| DE19608137A1 (de) * | 1996-03-02 | 1997-09-04 | Meyer Lucas Gmbh & Co | Lipid-Zubereitungen für diätetische Zwecke |
| WO1999029335A1 (en) * | 1997-12-05 | 1999-06-17 | Chong Kun Dang Corp. | Pharmaceutical composition containing cyclosporin |
| US6284268B1 (en) | 1997-12-10 | 2001-09-04 | Cyclosporine Therapeutics Limited | Pharmaceutical compositions containing an omega-3 fatty acid oil |
| WO1999029300A1 (en) | 1997-12-10 | 1999-06-17 | Rtp Pharma Inc. | Self-emulsifying fenofibrate formulations |
| AU3843999A (en) * | 1998-05-07 | 1999-11-23 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
| GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| US20050037065A1 (en) | 1999-05-27 | 2005-02-17 | Drugtech Corporation | Nutritional formulations |
| EP1157692B1 (en) * | 2000-05-22 | 2005-10-05 | Pro Aparts - Investimentos E Consultoria Lda | Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use |
| EP1279400A1 (en) * | 2001-07-25 | 2003-01-29 | Target Hit sa | Modifying the fatty acid composition of cell membranes of organs and tissues |
| KR100441167B1 (ko) | 2001-12-27 | 2004-07-21 | 씨제이 주식회사 | 마이크로에멀젼 예비 농축액 조성물 |
| ITMI20020269A1 (it) * | 2002-02-12 | 2003-08-12 | Victorix Assets Ltd | Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca |
| GB0210212D0 (en) | 2002-05-03 | 2002-06-12 | Univ Southampton | Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability |
| ITMI20022511A1 (it) | 2002-11-26 | 2004-05-27 | Victorix Assets Ltd | Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale. |
| US20040254357A1 (en) | 2002-12-19 | 2004-12-16 | Zaloga Gary P. | Fatty acid phenolic conjugates |
| AU2003288606A1 (en) | 2002-12-20 | 2004-07-14 | Pronova Biocare As | Use of a fatty acid composition for treatment of male infertility |
| SE0303513D0 (sv) * | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| GB0403247D0 (en) * | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
| GB0413730D0 (en) * | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
| GB0413729D0 (en) | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
| WO2006017692A2 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
| US20090030077A1 (en) * | 2004-08-06 | 2009-01-29 | Transform Pharmaceuticals Inc. | Novel Fenofibrate Formulations and Related Methods of Treatment |
| KR20070038553A (ko) * | 2004-08-06 | 2007-04-10 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 신규한 스타틴 약제학적 조성물 및 관련된 치료방법 |
| EP2377532A1 (en) * | 2004-08-18 | 2011-10-19 | Ace ApS | Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists for treating dermatological disorders |
| US20060051462A1 (en) * | 2004-09-03 | 2006-03-09 | Wang Jimmy X | Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients |
| CN101098690A (zh) * | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
| GB0428384D0 (en) * | 2004-12-24 | 2005-02-02 | Sla Pharma Ag | Eicosapentaenoic acid |
| EP1845999A4 (en) * | 2005-01-24 | 2010-09-22 | Pronova Biocare As | USE OF A DHA-CONTAINING FATTY ACID COMPOSITION FOR THE PRODUCTION OF A PHARMACEUTICAL OR FOOD PRODUCT FOR THE TREATMENT OF AMYLOSIS RELATED DISEASES |
| MX2007011031A (es) | 2005-03-08 | 2008-04-21 | Reliant Pharmaceuticals Inc | Tratamiento con estatina y acidos grasos omega-3 y un producto de combinacion de los mismos. |
| CN101217952B (zh) | 2005-07-08 | 2014-03-12 | 持田制药株式会社 | 用于预防心血管事件发病的组合物 |
| ITMI20051560A1 (it) * | 2005-08-10 | 2007-02-11 | Tiberio Bruzzese | Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6 |
| EP1968567B1 (en) | 2005-12-20 | 2014-06-18 | Cenestra, Llc | Omega 3 fatty acid formulations |
| US20090017118A1 (en) | 2006-02-10 | 2009-01-15 | Sportscom Danmark Aps | Coated tablets, their methods of preparation, and related uses |
| MY153288A (en) * | 2006-06-28 | 2015-01-29 | Hovid Berhad | An effective pharmaceutical carrier for poorly bioavailable drugs |
| JP2009544701A (ja) * | 2006-07-21 | 2009-12-17 | リライアント・ファーマシューティカルズ・インコーポレイテッド | オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用 |
| JP2009544702A (ja) | 2006-07-21 | 2009-12-17 | リライアント・ファーマシューティカルズ・インコーポレイテッド | 抵抗性高血圧症の治療に使用するオメガ−３脂肪酸 |
| US7676518B2 (en) | 2006-08-16 | 2010-03-09 | Sap Ag | Clustering for structured data |
| WO2008088415A1 (en) | 2006-10-18 | 2008-07-24 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids for reduction of lp-pla2 levels |
| WO2008113177A1 (en) * | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| RU2009139002A (ru) | 2007-03-23 | 2011-04-27 | Новартис АГ (CH) | Применение замаскированной или с нанесенным на нее покрытием соли меди для лечения дегенерации желтого пятна |
| US20080261896A1 (en) | 2007-04-11 | 2008-10-23 | Sinphar Pharmaceutical Co., Ltd. | Testosterone generating and metabolizing enhancer |
| US20090011012A1 (en) | 2007-07-06 | 2009-01-08 | Baum Seth J | Fatty acid compositions and methods of use |
| EP2239882A4 (en) | 2008-01-04 | 2016-11-02 | Univ Yamanashi | PROCEDURE FOR CONFIDENTIAL COMMUNICATION |
| EP2455070A1 (en) | 2008-01-10 | 2012-05-23 | Takeda Pharmaceutical Company Limited | Capsule Formulation |
| US20100062057A1 (en) | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
| WO2010040012A1 (en) | 2008-10-01 | 2010-04-08 | Martek Biosciences Corporation | Compositions and methods for reducing triglyceride levels |
| CN102421422A (zh) * | 2009-03-09 | 2012-04-18 | 普罗诺瓦生物医药挪威公司 | 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途 |
| ES2661812T3 (es) | 2009-10-16 | 2018-04-04 | Mochida Pharmaceutical Co., Ltd. | Composiciones |
| ES2895477T3 (es) | 2009-10-23 | 2022-02-21 | Basf As | Cápsulas y comprimidos revestidos de una mezcla de aceites de ácidos grasos |
-
2010
- 2010-03-09 CN CN2010800203059A patent/CN102421422A/zh active Pending
- 2010-03-09 EP EP10750438.3A patent/EP2405902B1/en active Active
- 2010-03-09 JP JP2011553553A patent/JP6176894B2/ja active Active
- 2010-03-09 US US13/255,595 patent/US11612579B2/en active Active
- 2010-03-09 WO PCT/IB2010/000791 patent/WO2010103402A1/en not_active Ceased
- 2010-03-09 KR KR1020187007824A patent/KR101966874B1/ko active Active
- 2010-03-09 ES ES10764152T patent/ES2979118T3/es active Active
- 2010-03-09 EP EP10764152.4A patent/EP2405903B1/en active Active
- 2010-03-09 SG SG2011065075A patent/SG174314A1/en unknown
- 2010-03-09 WO PCT/IB2010/000824 patent/WO2010103404A1/en not_active Ceased
- 2010-03-09 US US13/255,602 patent/US9532963B2/en active Active
- 2010-03-09 KR KR1020197009512A patent/KR102118478B1/ko active Active
- 2010-03-09 EA EA201171113A patent/EA022028B1/ru not_active IP Right Cessation
- 2010-03-09 CN CN201410322762.3A patent/CN104146955A/zh active Pending
- 2010-03-09 ES ES10750436T patent/ES2881885T3/es active Active
- 2010-03-09 CA CA3065860A patent/CA3065860A1/en not_active Abandoned
- 2010-03-09 PH PH12019500030A patent/PH12019500030A1/en unknown
- 2010-03-09 BR BRPI1009431A patent/BRPI1009431A2/pt not_active Application Discontinuation
- 2010-03-09 ES ES10750438T patent/ES2894340T3/es active Active
- 2010-03-09 US US13/255,587 patent/US11395811B2/en active Active
- 2010-03-09 CN CN201910497672.0A patent/CN110538148A/zh active Pending
- 2010-03-09 MX MX2011009503A patent/MX2011009503A/es unknown
- 2010-03-09 EP EP21186673.6A patent/EP3915554A1/en active Pending
- 2010-03-09 EP EP10750436.7A patent/EP2405895B1/en active Active
- 2010-03-09 NZ NZ595204A patent/NZ595204A/en unknown
- 2010-03-09 AU AU2010222648A patent/AU2010222648B2/en active Active
- 2010-03-09 CA CA2754860A patent/CA2754860C/en active Active
- 2010-03-09 WO PCT/IB2010/000788 patent/WO2010119319A1/en not_active Ceased
- 2010-03-09 KR KR1020117023450A patent/KR101841756B1/ko active Active
-
2011
- 2011-09-08 IL IL215043A patent/IL215043A/en not_active IP Right Cessation
- 2011-10-03 CO CO11130069A patent/CO6501136A2/es not_active Application Discontinuation
-
2015
- 2015-12-25 JP JP2015253166A patent/JP6723009B2/ja active Active
-
2016
- 2016-11-14 US US15/350,522 patent/US10028928B2/en active Active
-
2018
- 2018-02-05 JP JP2018018093A patent/JP2018090600A/ja active Pending
- 2018-07-23 US US16/043,097 patent/US10596142B2/en active Active
-
2020
- 2020-02-06 JP JP2020018504A patent/JP7199389B2/ja active Active
- 2020-03-24 US US16/828,062 patent/US11523999B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7199389B2 (ja) | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 | |
| JP6835664B2 (ja) | 脂肪酸油混合物の被覆型カプセル剤および錠剤 | |
| JP2013508348A5 (cg-RX-API-DMAC10.html) | ||
| JP2013537185A (ja) | 遊離酸の形のｅｐａおよびｄｈａを含む脂肪酸油混合物と界面活性剤とスタチンとを含む組成物 | |
| JP2013537186A (ja) | 脂肪酸油混合物と遊離脂肪酸とスタチンとを含む組成物 | |
| US20230218560A1 (en) | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof | |
| TW201311294A (zh) | 含脂肪酸油混合物、界面活性劑與司它汀（ｓｔａｔｉｎ）的組成物 |